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Abstract Women of childbearing age with recognized hep-
atitis B infection should have their liver disease assessed
before pregnancy occurs since the management of hepatitis
B virus (HBV) infection in this setting is complex. Initiation
of treatment in a woman of child-bearing age will depend on
when she intends on conceiving, as well as the severity of
her liver disease. During pregnancy, all decisions about
initiating, continuing or stopping HBV therapy must include
an analysis of the risks and benefits for both mother and
fetus. The trimester of the pregnancy and the stage of the
mother’s liver disease are important factors. Treatment in
the third trimester may be considered to aid in prevention of
perinatal transmission, which appears to be most pro-
nounced in mothers with high viral loads. Consideration of
initiation of third trimester treatment should occur after a
high viral load is documented in the latter part of the second
trimester, to allow adequate time for initiation of antiviral
therapy with significant viral suppression before delivery.
This discussion should include the topic of breastfeeding,
since it is generally not recommended while on antiviral
therapy. Until recently lamivudine and tenofovir appeared to
be the therapeutic options with the most reasonable safety
data in pregnancy. There are emerging data that telbivudine
may also be considered in this setting.
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Introduction
It is estimated that 350–400 million individuals worldwide
are chronically infected with HBV [1]. In regions with high
prevalence, infection is most commonly acquired through
either perinatal or horizontal transmission [2, 3]. The risk of
progression to chronic HBV infection is inversely propor-
tional to the age at which the infection was acquired. With-
out immunoprophylaxis, up to 90 % of infants born to
hepatitis B e antigen (HBeAg)-positive mothers become
infected. In contrast, only 20 % to 30 % of children exposed
between age 1 and 5 years, and fewer than 5 % of adults
become infected [4–6]. Thus, women of childbearing age
with chronic HBV infection remain an important source for
continued viral transmission.
This article will address a number of issues pertinent to
hepatitis B therapy in pregnancy. First, the woman of child-
bearing age who may require therapy for hepatitis B with
particular emphasis on the timing of therapy, choice of agent
and the patient’s desire to conceive in the future will be
discussed. Second, an approach to the woman who is newly
diagnosed with hepatitis B early in pregnancy will be out-
lined. In addition, whether therapy should be continued,
switched or stopped if an HBV-infected woman is on treat-
ment and becomes pregnant will be debated. Finally, the
question of whether a pregnant woman should be treated in
the third trimester to help prevent perinatal transmission will
be addressed in a proposed algorithm for the management of
HBV in pregnancy.
Therapy for HBV in Women of Childbearing Age
There are currently seven therapies FDA-approved for the
treatment of hepatitis B, including interferon (both standard
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and tenofovir [3]. Factors that will influence treatment
choice in women of childbearing age include safety in
pregnancy and breastfeeding, efficacy of the agent, intrinsic
barrier to resistance and proposed length of therapy. If
pregnancy is being contemplated in the near future, it may
be prudent to delay therapy until after the child is born [7].
This approach requires a careful assessment of the degree of
hepatic activity and fibrosis with either liver biopsy or non-
invasive methods. Although it is not recommended in a
pregnant woman, interferon can be used in the woman of
childbearing age, since therapy with this agent is for a
defined period (48 weeks) and often results in clinical re-
mission with HBeAg seroconversion [8]. This is in contrast
to the oral antiviral agents that generally require long-term
therapy and result in much lower rates of HBeAg serocon-
version [3, 7].
For those who require antiviral therapy, it is advis-
able to discuss the issue of pregnancy before starting
treatment. A “planned pregnancy” is preferable and may
influence the choice and timing of therapy, or potential-
ly the timing of pregnancy. In addition, given the rela-
tive paucity of evidence for most recommendations,
decisions about treatment during pregnancy can be
made with the luxury of time for consideration of all
relevant issues. Treatment with tenofovir is an ideal
choice, given its efficacy, high barrier to resistance and
safety profile in pregnancy [9, 10]. Lamivudine and
telbivudine, two alternate agents considered safe in preg-
nancy have a substantial incidence of antiviral resistance
with prolonged therapy and therefore are no longer first
line agents in the non-pregnant patient [3, 7, 10].
Newly Diagnosed Chronic HBV in Pregnancy
The pregnant woman who is newly diagnosed with HBV
early in pregnancy should undergo an assessment of her
infection. Decisions about initiating therapy in this setting
must include consideration of the risks and benefits for both
the mother and the fetus. The risk-benefit equation also
depends upon the trimester of the pregnancy. The major
determinant of the need for HBV therapy for the mother is
the severity of her liver disease (both hepatic activity and
fibrosis) [7]. Treatment is generally recommended if the
mother is at risk of hepatic decompensation. Most women
of childbearing age are likely to have mild disease and thus,
treatment can be safely postponed until after delivery. Since
many of these women are in the immune tolerant phase of
infection (high serum HBV DNA levels with normal ALT
and inactive liver biopsy), there is generally no need for
therapy and no indication to start therapy during the early
stages of pregnancy [3, 7].
Therapy for Hepatitis B in Early Pregnancy
No antiviral agent has been FDA-approved for use in preg-
nancy. Thus, when a woman receiving HBV antiviral ther-
apy becomes pregnant, a decision needs to be made whether
she should continue therapy for the duration of the pregnan-
cy or if therapy should be withdrawn . As with many
decisions during pregnancy, the health of the mother and
the fetus must be considered independently. From the per-
spective of the fetus, the major concern is the risk of expo-
sure to medication during early embryogenesis. From the
perspective of the mother, the major issue is whether inter-
ruption of antiviral therapy will adversely affect both short
and long-term liver disease outcomes. In general, if the
mother is known to have significant fibrosis, therapy should
be continued since the risk of a flare with withdrawal of
therapy could result in decompensation of her liver disease.
This effect on the mother’s health could also impact the
health of the fetus.
All oral HBVantivirals are inhibitors of either nucleoside
or nucleotide polymerases. Although these drugs preferen-
tially target the RNA-dependent DNA polymerase of HBV,
they also interfere with replication of mitochondrial DNA
and this can result in mitochondrial toxicity leading to the
lactic acidosis syndrome [11]. While lactic acidosis syn-
drome is very uncommon in adults, less is known about
the potential ramifications of mitochondrial toxicity in the
developing fetus. These may be more diverse, as toxicity
may affect organogenesis.
Safety data on HBV antivirals during pregnancy come
from two major sources, the antiretroviral pregnancy regis-
try (APR) [10] and also the Development of AntiRetroviral
Therapy Study (DART) [12]. The APR is an international,
voluntary, prospective exposure registration cohort study of
women exposed to antiretroviral therapies, most of whom
are HIV-1 mono-infected. As of July 2011, data from 13,507
pregnancies were available. However, this included only
175 women with HBV mono-infection. Table 1 shows the
Table 1 Antiretroviral pregnancy registry data
Proportion of defects
reported with an
exposure to:
Earliest trimester of exposure
1st trimester birth
defects/live births
2nd/3rd trimester birth
defects/live births
Lamivudine 122/3966 (3.1 %) 178/6427 (2.8 %)
Tenofovir 27/1219 (2.2 %) 15/714 (2.1 %)
Telbivudine 0/8 0/9
Adefovir dipivoxil 0/43 0/0
Entecavir 1/30 0/2
Any NRTI 165/5582 (3.0 %) 216/7772 (2.5 %)
Any NtRTI 27/1262 (2.1 %) 15/712 (2.1 %)
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birth defects for each of the FDA-approved HBVantivirals.
There was no significant difference in the rate of adverse
outcomes reported if the initial exposure of any nucleoside
or nucleotide drug was in the first trimester (3.0 % and
2.1 %) compared to the second or third trimester (2.5 %
and 2.1 %) of pregnancy. In addition, these rates compare
favorably to the background 2.72 % rate of defects reported
by the CDC birth defect surveillance system. Although these
are reassuring data, it is important to look at the experience
with each HBVagent. Lamivudine and tenofovir are the two
agents with the most in vivo experience in the first trimester
and appear to be safe. For telbivudine and entecavir only
8 and 30 pregnancies respectively with exposure in the first
trimester are recorded in the registry, with no adverse out-
comes reported. Although the APR is extremely useful, it
does have limitations including short follow-up and that
only defects identified at birth are recorded. Developmental
anomalies, such as cardiac or neurological defects identified
at a later date, may therefore not be captured.
The DART study is a 6 year, multi-center, randomized
trial of antiretroviral therapy among adults with symptom-
atic HIV-1 infection or advanced disease/AIDS in Africa.
The 3 % rate of congenital anomalies reported in this study
also compares favorably to the 2.72 % reported by the CDC
birth defect surveillance system [12].
Continuing, Switching or Discontinuing Therapy?
If the decision is made to continue HBV therapy during
pregnancy, the question then becomes whether the drug
should be replaced with an agent that has more in vivo
experience during pregnancy (i.e. is thought to be “safer”).
For example, because of the lack of safety data for entecavir,
and because it is an FDA pregnancy class C drug (see Table 2
for FDA pregnancy class definitions [13]), consideration
should be given to switching to another agent. Although, the
two most commonly used agents in pregnancy are lamivudine
and tenofovir, there is a growing experience with telbivudine.
Lamivudine is also categorized as a class C agent by the FDA
because of reports of toxicity in rabbits with first trimester
exposure. However, since it was the first oral agent approved
for the treatment of HBV, extensive clinical experience exists.
The APR data also suggest that lamivudine is safe despite its
pregnancy C classification. However, resistance with short-
term use of lamivudine in the third trimester has now been
reported [14]. Although there is less clinical experience with
tenofovir, it is categorized as a Class B agent by the FDA and
has the added benefit of a very high genetic barrier to resis-
tance, with no reported resistance identified to date [13, 15].
Telbivudine, another class B agent [13],has beenseldomused
for two reasons. Firstly, until the recently published reports
that telbivudine reduces perinatal transmission (see section
entitled “Evidence for treatment in the third trimester”), there
has been minimal in vivo experience in pregnancy with this
drug. In addition, it has a low barrier to resistance [16].
Rather than switching agents, withdrawal of treatment for
the duration of pregnancy may be preferable, especially to
the mother who wants to avoid any potential future risk to
the fetus. What would be the consequence to the mother of
stopping treatment altogether? The natural history of chron-
ic HBV in pregnancy has not been well described. There are
limited data to suggest that rarely severe complications of
HBV occur late in pregnancy, with reports of liver failure
requiring liver transplantation in previously asymptomatic
individuals [17]. Data specifically addressing the risk of
stopping therapy during pregnancy are anecdotal. Our
knowledge of those risks relating to cessation of therapy is
derived from early clinical trials in nonpregnant patients,
with less advanced fibrosis. In these early studies, therapy
was stopped after completion of the trial – even for patients
who remained HBeAg(+). Follow-up confirmed that HBV
DNA levels rebounded, but rarely did this result in clinically
Table 2 FDA pregnancy categories
Pregnancy Category A Adequate and well controlled human studies have failed to demonstrate a risk to the fetus in the first trimester
of pregnancy (and there is no evidence of risk in later trimesters)
Pregnancy Category B Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well
controlled studies in pregnant women or animal studies have shown an adverse effect, but adequate and
well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester
Pregnancy Category C Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well
controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite
potential risks
Pregnancy Category D There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing
experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite
potential risks
Pregnancy Category X Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human
fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in
use of the drug in pregnant women clearly outweigh potential benefits
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patients with severe fibrosis or cirrhosis at baseline, flares
upon treatment withdrawal can result in overt hepatic de-
compensation [20].
Overall, it appears the risk of an adverse outcome with
continuing antiviral therapy during pregnancy is likely very
low. However, therapy could be discontinued with close
observation of the mother to avoid continued fetal exposure
during the first trimester, especially in the patient who does
not have advanced fibrosis.
Rationale for Third Trimester Treatment
The majority of perinatal transmission is thought to occur at
delivery, since a combination of passive immunization with
hepatitisBimmunoglobulin(HBIG)givenwithin12hofbirth
and passive immunization with three doses of the hepatitis B
vaccine in the first 6 months of life has resulted in prevention
of the majority of infections in this setting. Early seminal
studies by Beasley and colleagues showed that HBIG admin-
istration could reduce the rate of HBV transmission from
>90 % from HBeAg(+) mothers down to ~26 % [21, 22].
When combined with the vaccine, the rates of transmission
fell to 3-7 % [23, 24]. In contrast, there have been no con-
vincing data that C-section lowers the rate of perinatal trans-
mission. In a recent retrospective study, 569 infants born to
HBeAg-positivemothers foundHBVinfectionin5.94% who
were delivered vaginally, 8.51 % who were delivered by
emergencyCaesareansection,and2.12%whoweredelivered
byelective Caesareansection [25].The researchers concluded
that elective Caesarean delivery may be the preferred delivery
choice to reduce infection risk. However, this has yet to be
validated prospectively.
Almost all vaccine and HBIG failures occur in HBeAg(+)
women with very high viral loads, generally above 10
8
copies/mL [26]. A recent report suggested an overall 3 %
perinatal transmission rate in viremic mothers despite the
use of immunoprophylaxis [27￿]. The rate was 7 % in
viremic HBeAg positive mothers and 9 % in those mothers
who had viral loads >10
8 copies/mL. Perinatal transmission
did not occur in HBeAg-positive mothers with viral loads
that were <10
8 copies/mL. This implies that high viral load,
rather than HBeAg status is the main factor for transmission.
This has raised the question of whether antiviral therapy
before delivery would lower the viral load adequately to
prevent transmission.
Rationale for Third Trimester Treatment
Should pregnant women who are HBsAg positive and high-
ly viremic receive antiviral therapy in the third trimester to
prevent perinatal transmission? No consensus on this issue
has yet been reached [7]. The principal of treatment late in
pregnancy to prevent or reduce the rate of perinatal trans-
mission has been established with other viruses. In HIV-
infected mothers antiretroviral therapy (including lamivu-
dine) leads to reduction of mother to child transmission of
HIV [28]. Antivirals have also been advocated late in preg-
nancy to prevent acquisition of neonatal herpes [29].
In a pilot study, 8 women with HBV DNA levels >10
9
copies/mL were administered lamivudine at 34 weeks of
gestation. Babies were vaccinated and received HBIG at birth
and only 1 became infected compared to 7 of 25 (28 %) cases
of transmission in a matched historical control population
[30]. This led to a randomized, double-blind placebo-
controlled trial of lamivudine to prevent transmission in high-
ly viremic HBeAg(+) women [31￿]. At 1 year of age, 18 % of
babies of lamivudine-treated mothers were HBsAg(+) com-
pared to 39 % in the placebo-treated arm. Both groups re-
ceived vaccination and HBIG. Based on these results, the
authors recommended treatment in the third trimester for
women with high viral loads. Unfortunately, due to major
problems with follow-up, the data are extremely hard to
interpret. At 1 year, 13 % of babies in the lamivudine arm
and 31 % in the placebo arm had been lost to follow-up.
Evaluating only those with complete data, there was a trend
but no significant difference in the rate of HBsAg positivity at
1 year (6 % lamivudine vs. 12 % placebo, p00.37). The study
was also very underpowered (power053 %), due to slow
recruitment. There were no consequences to mother or baby
with lamivudine treatment in the study. More recently a meta-
analysis to evaluate the efficacy of lamivudine in reducing in
utero transmission of HBV has been reported [32￿]. A total of
ten randomized controlled trials (RCTs) examining 951 HBV-
carrier mothers were included [31￿, 33–41]. The RCTs evalu-
ated included newborns that received immunoprophylaxis at
birth and women were treated with lamivudine from 24–
32 weeks of gestation until delivery to 1 month post-
delivery. Newborns in the lamivudine group had a 13 % to
24 % significantly lower incidence of intrauterine exposure,
indicated by newborn HBsAg (p00.04) and HBV DNA (p<
0.001) positivity. In addition, newborns in the lamivudine
treated group had a 1.4-2 % lower perinatal infection rate
at 9–12 months indicated by HBsAg (p<0.01) and HBV
DNA (p<0.001) seropositivity. This report was limited by
the quality of the studies included (most studies were only
rated 3 of 5 on the Jadad score [42]) and the heterogene-
ity of the definition used for high viral load that prompted
therapy. A second meta-analysis also reported a decrease
in perinatal transmission with the use of lamivudine, but
only if the viral load was reduced to <10
6 copies/mL [43].
In a small study of 31 pregnant women in China, treatment
with telbivudine was commenced between 28 and 32 weeks
and was continued to 30 days post-partum [44]. Compared
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similar viral loads at baselineand atparturition, the viral loads
in the patients treated with telbivudine reduced significantly
from 7.38 log10 at baseline to 4.08 log10 prior to parturition
(p<0.01). All babies received active and passive immunopro-
phylaxis. The infection rate was 0 % in those treated with
telbivudine and 13.3 % in the untreated controls. Two recent
studies have confirmed a reduction in perinatal transmission
with telbivudine [45￿￿, 46￿￿]. In the larger of the 2 studies,
researchers prospectively enrolled 229 mothers with HBV
DNA levels greater than 10 million copies per mL in an
open-label trial. From gestational week 20 to week 32, 135
of the women received telbivudine 600 mg/day, while 94
served as controls. All the infants were given HBIG within
12 h postpartum, and received HBV vaccine at 0, 1 and
3 months. Prior to delivery every telbivudine-treated mothers
had >3log10 reduction in HBV DNA levels, whereas the viral
loads in the untreated mothers remained unchanged. Further-
more, 44 (33 %) of the telbivudine-treated mothers and none
(0 %) of the untreated controls had undetectable viremia at
delivery. Seven months after delivery, the incidence of peri-
natal transmission was lower in the infants that completed
follow-up born to the telbivudine-treated mothers than to the
controls (0 % vs 8 %; p00.002). In the second study, of 88
pregnant women with viral loads of >6 log10 copies/mL, 53
were administered telbivudine starting in the second or third
trimester and 35 received no treatment. All infants received
standardimmunoprophylaxisafterbirth.At28weeks,noneof
the infants whose mothers received telbivudine had immuno-
prophylaxis failure, whereas 8.6 % of the infants of control
mothers did (P00.029). In both studies, no serious adverse
events were noted in the telbivudine-treated mothers or their
infants.Althoughalargenumberofpatientswereenrolledand
followed prospectively, the followup of the infants was rela-
tively short. Nevertheless, they contain important data sup-
porting the use of antiviral therapy in the third trimester.
There are no comparable data on efficacy of tenofovir .
However, it would be expected that tenofovir would be at
least equally effective as lamivudine and telbivudine in
reducing perinatal transmission given its potency. This to-
gether with its high barrier to resistance makes it an attrac-
tive agent to consider in the third trimester.
Overall, additional randomized, multi-center, long-term
follow-up studies are needed to better define the utility of
antiviral agents in preventing perinatal transmission. In ad-
dition, although a high viral load is clearly important, it is
not the only factor predisposing to failure of immunopro-
phylaxis. This is highlighted by a case in which a child
developed chronic HBV infection despite suppression of
HBV DNA to undetectable levels in the mother with lam-
ivudine therapy throughout gestation and appropriate immu-
noprophylaxis after birth [47]. Rarely infection may occur in
utero, particularly in the setting of threatened pre-term labor
with very high maternal viral loads [48]. Furthermore, long-
term safety data are lacking and potential risks to the mother
include the development of antiviral resistance [14]a n d
flare of hepatitis after treatment withdrawal. In one study
42 % of those who did not receive antiviral therapy during
pregnancy experienced a flare in the postpartum period
compared to 62 % among those who had been treated and
then discontinued therapy at delivery [49]. More recently, it
was reported that none of the thirty-eight women who
withdrew telbivudine one month post-partum developed
severe hepatitis (defined as an ALT>10 x ULN) [45￿￿].
Algorithm for Management of HBV in the Pregnant
Patient
An algorithm for the management and treatment of HBV in
pregnancy is proposed in Fig. 1. Routine antepartum care
includes testing a woman for the presence or absence of
hepatitis B in the first trimester. If she is negative, her child
will be vaccinated at birth. The mother does not have to be
vaccinated during pregnancy, although it is considered safe
and should therefore be administered to those with high risk
behavior for acquisition.
For those who test positive early in pregnancy, an assess-
ment of the mother’s HBV status should occur, including a
hepatic panel, HBV serologies and platelet count. If the
patient has very active HBV (significantly elevated ALT
with a high viral load), or if cirrhosis is suspected (low
platelet count or suggestive imaging), then therapy should
be initiated regardless of trimester. Sequencing of the virus
prior to initiating therapy can be considered to aid in decid-
ing which antiviral to use, since primary resistance has been
reported [50]. However, if therapy is not warranted (inactive
disease with low ALT and low viral load), continued sur-
veillance is suggested since pregnancy can result in a flare
of hepatitis B both later in pregnancy and for several months
post-partum [17, 49].
It is recommended that all women have their HBV DNA
viral load quantified toward the end of the second trimester (at
26–28 weeks gestation) so that a final decision regarding
therapy can occur shortly thereafter. This will allow enough
time in the third trimester to significantly decrease the viral load
after therapy is initiated to decrease perinatal transmission .
Women with high viral loads (>200,000 IU/mL or >10
6 cop-
ies/mL) should be considered for therapy early in the third
trimester (28–30 weeks), after a thorough discussion of the
risks and benefits, since dataare too limited to mandate therapy.
Once started, therapy is continued for the duration of the
pregnancy and can be discontinued post-partum if desired.
The decision to discontinue therapy is often influenced by the
woman’s desire for subsequent pregnancies. The timing of
discontinuation of therapy post-partum remains unclear. In
86 Curr Hepatitis Rep (2012) 11:82–89published studies therapy is discontinued anywhere from
birth to 1 month post delivery [32￿]. In practice, therapy
is often continued up to 6 months post-partum. Regard-
less of when therapy is discontinued, there is a small
but real risk of flare and the mother should be moni-
tored closely after withdrawal for at least 6 months.
Another factor that may influence the timing of discon-
tinuation of treatment post-partum is the mother’sd e s i r e
to breastfeed. There are few data regarding the safety of
breastfeeding while on antiviral therapy and thus,
breastfeeding while on treatment for HBV is not recom-
mended [51, 52].
When deciding on therapy in the third trimester, the perinatal
transmission outcome of prior pregnancies must be considered.
If previous pregnancies did not result in perinatal transmission,
then a viral load of >200,000 IU/mL (10
6copies/mL) should be
used to determine if therapy should be initiated (similar
to the woman who has had no previous children). How-
ever, if perinatal transmission did occur with a prior
pregnancy, then the risk of perinatal transmission in
the current pregnancy is likely higher [7]. In such cases,
strong consideration for initiating therapy in the third
trimester, regardless of the mother’s viral load at the end of
the second trimester is recommended.
Transmission of HBV Infection in Breastfed Babies
Although early studies did claim that HBV transmission
could occur through breast milk, more recent studies have
Fig. 1 An algorithm for management of HBV in the pregnant patient.
Legend: HBsAg 0 hepatitis B surface antigen, HBcAb 0 hepatitis B
core antibody (total), HBsAb 0 hepatitis B surface antibody, HBeAg 0
hepatitis B e antigen, HBeAb 0 hepatitis B e antibody, ** discontinue
therapy between 0 and 6 months-ideal time to discontinue remains
unclear
Curr Hepatitis Rep (2012) 11:82–89 87shown that similar rates of acquisition through breast-
milk fed and formula-fed babies. In 1975, before the
availability of neonatal immunization, the rates of ac-
quisition of HBV were found to be 53 % in breastfed
a n d6 0%i nf o r m u l a - f e db a b i e sb o r nt oH B s A gp o s i t i v e
mothers [53]. These data are limited since the high
vertical transmission rates confounded the true rate of
acquisition from breast-feeding. After the introduction of
immunoprophylaxis, Hill et al. found a similar rate infec-
tion rate of breast-fed and formula-fed infants (0 % and
3% )[ 54]. A recently published meta-analysis confirms
that breastfeeding after proper immunoprophylaxis does
not contribute to mother-child transmission of the virus
[55]. Thus, current guidelines state that breastfeeding is
not contraindicated in HBV-infected mothers not on
antiviral therapy whose infants receive immunoprophy-
laxis [3].
For mothers on antiviral therapy breastfeeding is not
recommended. According to prescribing information, it has
not been recommended that women breastfeed their infants
while taking lamivudine or tenofovir to avoid risking post-
natal transmission of HIV-1 infection [51, 52]. Although it is
known that lamivudine and tenofovir are both excreted into
human breast milk, little is known about the extent of
exposure of antiviral agents during breastfeeding. Thus,
overall little is known about the safety of breastfeeding in
this setting.
Conclusions
Factors to consider when deciding whether HBV therapy is
warranted for either the woman of childbearing age or the
one who is pregnant, include extent of existing liver disease,
efficacy and safety of existing FDA-approved antiviral
agents. Although none of these agents are approved for the
use in this setting, there is increasing safety data emerging.
With this, there are fewer delays in treating those pregnant
women who have clinically active disease. Although it
remains unclear if therapy that is initiated in the third tri-
mester in highly viremic mothers reduces perinatal trans-
mission, published reports suggesting a benefit are
emerging. Additional randomized, multicenter, long-term
follow-up studies are needed.
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